Roth Capital began coverage on shares of Juniper Pharmaceuticals (NASDAQ:JNP) in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage issued a buy rating and a $12.00 price target on the specialty pharmaceutical company’s stock.

A number of other research firms also recently weighed in on JNP. HC Wainwright reissued a neutral rating on shares of Juniper Pharmaceuticals in a report on Monday, November 6th. ValuEngine raised Juniper Pharmaceuticals from a hold rating to a buy rating in a report on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The company has an average rating of Hold and a consensus price target of $23.00.

Juniper Pharmaceuticals (NASDAQ JNP) opened at $5.35 on Tuesday. Juniper Pharmaceuticals has a 1-year low of $3.65 and a 1-year high of $6.10. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.00 and a quick ratio of 1.68. The firm has a market capitalization of $59.10, a PE ratio of 8.52 and a beta of 0.04.

A number of hedge funds have recently bought and sold shares of JNP. Goldman Sachs Group Inc. increased its position in Juniper Pharmaceuticals by 3.4% in the second quarter. Goldman Sachs Group Inc. now owns 21,735 shares of the specialty pharmaceutical company’s stock worth $110,000 after buying an additional 715 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Juniper Pharmaceuticals by 1.9% in the second quarter. Dimensional Fund Advisors LP now owns 72,875 shares of the specialty pharmaceutical company’s stock worth $368,000 after buying an additional 1,344 shares in the last quarter. Algert Global LLC increased its position in Juniper Pharmaceuticals by 20.4% in the third quarter. Algert Global LLC now owns 144,565 shares of the specialty pharmaceutical company’s stock worth $658,000 after buying an additional 24,530 shares in the last quarter. Macquarie Group Ltd. purchased a new stake in Juniper Pharmaceuticals in the third quarter worth about $129,000. Finally, Nationwide Fund Advisors increased its position in Juniper Pharmaceuticals by 5,500.0% in the second quarter. Nationwide Fund Advisors now owns 56,000 shares of the specialty pharmaceutical company’s stock worth $283,000 after buying an additional 55,000 shares in the last quarter. 36.39% of the stock is currently owned by institutional investors.

WARNING: “Roth Capital Begins Coverage on Juniper Pharmaceuticals (JNP)” was published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.watchlistnews.com/roth-capital-begins-coverage-on-juniper-pharmaceuticals-jnp/1797077.html.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.

Receive News & Ratings for Juniper Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.